Nonetheless, these associations warrant cautious interpretation, as contemporary evidence does not substantiate the clinical utility of MTHFR and PAI-1 genotyping within standard thrombophilia screening protocols. This evidence concerns the gene MTHFR and Rare hereditary thrombophilia.